Filters

Pp-212 manufacturers

Filters

None products found

pp-212

Tablets

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA, Taiwan
Comments
Indication: Alzheimer's disease — targeting neuroinflammation in early-to-moderate AD Clinical stage: Phase 2 — approved by Taiwan FDA (TFDA) September 2023; Phase 2 trial ongoing Modality: Small molecule (selective, brain-penetrant CSF-1R inhibitor) Mechanism / Target: Selective inhibitor of colony stimulating factor 1 receptor (CSF-1R) with good blood-brain barrier penetration; specifically suppresses activated microglia by blocking CSF-1R-driven microglial proliferation and pro-inflammatory activation; reduces neuroinflammation-related gene expression (TREM2, Iba1) while preserving normal microglial surveillance function Route / form: Oral tablet/capsule Differentiation: First brain-penetrant CSF-1R inhibitor targeting neuroinflammation in Alzheimer's — a mechanism entirely distinct from amyloid/tau approaches;
Manufacturer #39349
Clinical-stage biotech developing Rx precision immunotherapies for Alzheimer's disease and vitiligo through innovative immune-targeting mechanisms. International team spanning Asia and North America advances a biologic pipeline through clinical development stages. Focused on immune mechanism-based approaches for underserved neurodegenerative and autoimmune conditions.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.